Loading...
•
Sep 30, 2022
ClearPoint Neuro Q3 2022 Earnings Report
Reported a revenue increase of 13% year-over-year, driven by growth in functional neurosurgery navigation and therapy revenue, biologics and drug delivery revenue, and capital equipment and software revenue.
Key Takeaways
ClearPoint Neuro reported a strong third quarter with a 13% increase in revenue year-over-year, reaching $5.1 million. The company reaffirmed its full-year 2022 revenue outlook of $21.0 to $22.0 million and highlighted the European Commission's marketing authorization for Upstaza, a gene therapy treatment to be administered with ClearPoint's SmartFlow® Neuro Cannula.
Reported quarterly revenue of $5.1 million, a 13% year-over-year increase.
Partner PTC Therapeutics’ gene therapy treatment Upstaza™ was granted full marketing authorization by the European Commission.
Added multiple new biologics and drug delivery partners in the quarter to bring the total to approximately 50.
Announced multiple FDA clearances: the ClearPoint Maestro™ Brain Model, the ClearPoint Prism™ Neuro Laser Therapy System and the 2.1 version of the ClearPoint Neuro Navigation software.
Revenue by Segment
Forward Guidance
The Company reaffirms its full year 2022 revenue outlook of between $21.0 and $22.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...